Isoniazid pharmacokinetics in patients in chronic renal failure. 1976

C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley

INH pharmcokinetics was studied in 2 groups of patients in chronic renal failure. In the group on conservative treatment, INH half life was prolonged, but was not related to the degree on renal impairement. In the hemodialysis group 73% of the INH given was removed by dialysis within 5 hours. If INH is to be used in the presence of renal failure, individual half life estimations should be performed in order to determine dosage frequency. In patients on hemodialysis, therapy should be given post dialysis. Alternatively, drugs not dependent on renal failure, e.g. rifampicin, may be preferable.

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
April 1983, Vrachebnoe delo,
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
April 1987, Clinical pharmacokinetics,
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
April 1984, Polskie Archiwum Medycyny Wewnetrznej,
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
January 1974, Revista de medicina de la Universidad de Navarra,
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
September 1992, Acta radiologica (Stockholm, Sweden : 1987),
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
November 1983, Anesthesiology,
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
January 1983, European journal of drug metabolism and pharmacokinetics,
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
April 2011, British journal of anaesthesia,
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
January 1984, European journal of clinical pharmacology,
C H Gold, and N Buchanan, and V Tringham, and M Viljoen, and B Strickwold, and G P Moodley
January 1983, European journal of clinical pharmacology,
Copied contents to your clipboard!